TScan Therapeutics

TScan Therapeutics is a fully integrated clinical-stage biotechnology company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer. Founded in early 2018, it began as a discovery-driven company using a novel target discovery platform and has since moved into clinical-stage development. Its current focus is on in vivo engineering of TCR-Ts to treat solid tumors, with lead candidates targeting PRAME and MAGE-A4. The company is headquartered in Waltham, United States.

TScan Therapeutics was founded in early 2018 to discover and develop TCR-T therapies using a novel target discovery platform. The company began as a discovery-driven organization and progressed through platform development, clinical candidate advancement, and clinical-stage development. Its stated focus has evolved toward in vivo engineering of TCR-Ts for solid tumors, and it has identified two lead candidates, one targeting PRAME and the other targeting MAGE-A4, to advance into IND-enabling studies.

Striving to become a leader in developing in vivo-engineered TCR-T therapy for the treatment of solid tumor indications.

• TSC-101

  Evaluated in Phase 3 ALLOHA-2™ pivotal trial in patients with heme malignancies

• 2021.01.07

  Reported2021.01.07

  TScan Therapeutics appoints Brian M. Silver to its board[5]TScan Therapeutics任命Brian M. Silver加入董事会biospace.com

  TScan Therapeutics announced Brian M. Silver's appointment to its board of directors.

Read more

1. 1TCR-T Cancer Therapies | TScan Therapeuticstscan.com
2. 2Clinical-Stage Biotech Company | About TScan Therapeuticstscan.com
3. 3Leadership Team | TScan Therapeuticstscan.com
4. 4TScan Therapeutics (United States)wikidata.org
5. 5TScan Therapeutics任命Brian M. Silver加入董事会biospace.com